Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT05680818 is registered in ClinicalTrials.gov with Calcilytix Therapeutics, Inc., a BridgeBio company as lead sponsor.

NCT NCT05680818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 6, 2023
Completion date
August 31, 2029
Enrollment
67 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant hypocalcemia (adh)